Our Science

We are focused on rapidly designing and developing new medicines based on breakthroughs in cancer research.

Targeting Resistance

Prelude is focused on the rapid design and development of small molecule agents that target known resistance mechanisms. Treatment emergent resistance resulting from primary resistance to the drug targets, acquired resistance through alterations in the same signaling pathway or signaling through alternative pathways that bypass a drug target’s primary mechanism of action are within the scope of Prelude’s research focus.